Feb 6, 2014
TSX Exchange Symbol: RVX
CALGARY, Feb. 6, 2014 /CNW/ - Resverlogix Corp. (TSX:RVX) will be hosting a conference call and webcast on Thursday, February 13, 2014 at 11 am MDT / 1 pm ET. The call will update the market on current clinical and business structure options.
Details for the conference call and webcast are as follows:
Link to webcast: http://services.choruscall.ca/links/resverlogix140213.html
Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340
About Resverlogix
Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and our IR App found on Apple products iTunes and Android users (Google Play).
| Company Contacts: | ||||
| Donald J. McCaffrey President and CEO Resverlogix Corp. Phone: 403-254-9252 Email: don@resverlogix.com | Kenneth Lebioda SVP Business & Corporate Development Resverlogix Corp. Phone: 403-254-9252 Email: ken@resverlogix.com |
SOURCE Resverlogix Corp.